Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
85 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Spasticity - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Spasticity - Pipeline Review, H1 2015', provides an overview of the Spasticity's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Spasticity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spasticity and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Spasticity - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Spasticity and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Spasticity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Spasticity pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Spasticity - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Spasticity pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Spasticity Overview 8 Therapeutics Development 9 Pipeline Products for Spasticity - Overview 9 Pipeline Products for Spasticity - Comparative Analysis 10 Spasticity - Therapeutics under Development by Companies 11 Spasticity - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Spasticity - Products under Development by Companies 15 Spasticity - Companies Involved in Therapeutics Development 16 Addex Therapeutics Ltd 16 Canbex Therapeutics Ltd. 17 Concert Pharmaceuticals, Inc. 18 Daewoong Pharmaceutical Co., Ltd. 19 Echo Pharmaceuticals B.V. 20 GW Pharmaceuticals plc 21 Ipsen S.A. 22 Merz Pharma GmbH & Co. KgaA 23 OBI Pharma, Inc. 24 Osmotica Pharmaceutical Corp. 25 Sanochemia Pharmazeutika AG 26 SciFluor Life Sciences, LLC 27 Sun Pharma Advanced Research Company Ltd. 28 Spasticity - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Target 30 Assessment by Mechanism of Action 32 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Drug Profiles 38 abobotulinumtoxin A - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 ADX-71441 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 arbaclofen ER - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 baclofen ER - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 CTP-354 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 dronabinol - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 incobotulinumtoxin A - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 nabiximols - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 NB-2221 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 OBI-858 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 onabotulinumtoxin A - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Small Molecule for Spasticity - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 tolperisone - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 VSN-16R - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Spasticity - Recent Pipeline Updates 58 Spasticity - Dormant Projects 71 Spasticity - Discontinued Products 73 Spasticity - Product Development Milestones 74 Featured News & Press Releases 74 Jan 26, 2015: Ipsen announces topline results of two double-blind phase III studies of Dysport in lower limb spasticity in children and in adults 74 Nov 28, 2014: Ipsen Announces FDA Acceptance of Filing for Dysport in the Treatment of Upper Limb Spasticity in Adult Patients 75 Nov 14, 2014: Ipsen Biopharmaceuticals Presents Dysport (abobotulinumtoxinA) Data at American Academy of Physical Medicine and Rehabilitation Annual Assembly 76 Oct 13, 2014: Concert Pharmaceuticals Presents Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate for the Treatment of Spasticity 77 Jul 16, 2014: Concert Pharmaceuticals Announces FDA Lifts Partial Clinical Hold for CTP-354, A Novel Drug Candidate for Spasticity 78 Jul 11, 2014: Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe 78 Apr 12, 2014: Ipsen announces a first set of results on positive phase III clinical study of Dysport in the treatment of adults suffering from Upper Limb Spasticity at the 8th World Congress for NeuroRehabilitation in Istanbul 79 Dec 17, 2013: Ipsen announces positive initial results from the international double-blind clinical phase III study of Dysport in the treatment of Adults suffering from Upper Limb Spasticity 80 Oct 02, 2013: GW Pharmaceuticals Announces New Sativex Data at ECTRIMS 81 Aug 14, 2013: GW Pharmaceuticals Opens an Investigational New Drug Application in the United States for a Sativex Phase 3 Clinical Program as a Treatment for Spasticity Due to Multiple Sclerosis 83 Appendix 84 Methodology 84 Coverage 84 Secondary Research 84 Primary Research 84 Expert Panel Validation 84 Contact Us 84 Disclaimer 85
List of Tables Number of Products under Development for Spasticity, H1 2015 9 Number of Products under Development for Spasticity - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 11 Comparative Analysis by Late Stage Development, H1 2015 12 Comparative Analysis by Clinical Stage Development, H1 2015 13 Comparative Analysis by Early Stage Development, H1 2015 14 Products under Development by Companies, H1 2015 15 Spasticity - Pipeline by Addex Therapeutics Ltd, H1 2015 16 Spasticity - Pipeline by Canbex Therapeutics Ltd., H1 2015 17 Spasticity - Pipeline by Concert Pharmaceuticals, Inc., H1 2015 18 Spasticity - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 19 Spasticity - Pipeline by Echo Pharmaceuticals B.V., H1 2015 20 Spasticity - Pipeline by GW Pharmaceuticals plc, H1 2015 21 Spasticity - Pipeline by Ipsen S.A., H1 2015 22 Spasticity - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2015 23 Spasticity - Pipeline by OBI Pharma, Inc., H1 2015 24 Spasticity - Pipeline by Osmotica Pharmaceutical Corp., H1 2015 25 Spasticity - Pipeline by Sanochemia Pharmazeutika AG, H1 2015 26 Spasticity - Pipeline by SciFluor Life Sciences, LLC, H1 2015 27 Spasticity - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 28 Assessment by Monotherapy Products, H1 2015 29 Number of Products by Stage and Target, H1 2015 31 Number of Products by Stage and Mechanism of Action, H1 2015 33 Number of Products by Stage and Route of Administration, H1 2015 35 Number of Products by Stage and Molecule Type, H1 2015 37 Spasticity Therapeutics - Recent Pipeline Updates, H1 2015 58 Spasticity - Dormant Projects, H1 2015 71 Spasticity - Dormant Projects (Contd..1), H1 2015 72 Spasticity - Discontinued Products, H1 2015 73
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
